Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Novartis plans to cut as many as 680 jobs in development, Sanofi's pipeline reprioritization project will result in layoffs.
April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment ...
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of ...
Analysts' ratings for Amgen (NASDAQ:AMGN) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The following table encapsulates their recent ratings, offering a glimpse ...
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is losing its research and development lead. In a Thursday filing with ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...